Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-cyclopentapyrimidine-1-acetamide
Purity: ≥98%
Formula Markup: C36H38F4N4O2S
Formula Weight: 666.8
CAS Number: 356057-34-6
Notes: Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor acetylhydrolase (PAF-AH) or phospholipase A2 group 7 (PLA2G7), hydrolyzes glycerophospholipids to produce lyso-PAF/lyso-phosphatidylcholine and short and/or oxidized fatty acids, many of which have pro-inflammatory or pro-oxidative activities.{26682,26483} Darapladib is a reversible inhibitor of Lp-PLA2 (IC50 = 0.25 nM).{27391} It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy.{27387} Lp-PLA2 inhibition with darapladib also reduces the development of coronary atherosclerotic plaques.{27388,27390}
Deutsch
English
